Development and validation of prescription drug risk, efficacy, and benefit perception measures in the context of direct-to-consumer prescription drug advertising

Suzanne L. West; Carla M. Bann; Douglas J. Rupert; Bridget J. Kelly; Brian G. Southwell; Sarah Angela Parvanta; Susana Carrie Peinado; Alexander Rabre; Nicole Antoinette Mack; Bridget J. Kelly; Douglas J. Rupert; KJ Aikin; HW Sullivan; M Johnson; Carla M Bann; Nicole Antoinette Mack; Brian G. Southwell; Sue West; Sarah Angela Parvanta; Alexander Rabre; Susana Carrie Peinado

Development and validation of prescription drug risk, efficacy, and benefit perception measures in the context of direct-to-consumer prescription drug advertising

Kelly, B. J., Rupert, D. J., Aikin, KJ., Sullivan, HW., Johnson, M., Bann, C. M., Mack, N. A., Southwell, B. G., West, S., Parvanta, S. A., Rabre, A., & Peinado, S. C. (2021). Development and validation of prescription drug risk, efficacy, and benefit perception measures in the context of direct-to-consumer prescription drug advertising. Research in Social and Administrative Pharmacy, 17(5), 942-955. https://doi.org/10.1016/j.sapharm.2020.07.028

Copy citation

Abstract

Purpose
Understanding patient perceptions of prescription drug risks and benefits is an important component of determining risk-benefit tradeoffs and helping patients make informed medication decisions. However, few validated measures exist for capturing such perceptions. The purpose of this study was to develop and validate measures of perception of prescription drug risk, efficacy, and benefit.

Methods
We conducted a mixed-methods study to develop and validate the measures, including three waves of quantitative testing (item nonresponse, criterion-related validity, and convergent validity). We conducted quantitative testing with a probability-based online consumer panel of U.S. adults (n = 7635), eliminating weaker items after each testing wave.

Results
Upon completion of all testing, we identified 21 validated measures that represent 11 distinct risk/benefit constructs. The final measures demonstrated face validity, convergent validity, criterion-related validity, and scale reliability in both illness and general population samples, among patients with both symptomatic and asymptomatic health conditions, and in response to both television and print direct-to-consumer prescription drug advertisements.

Conclusions
Our study produced a set of items that researchers and practitioners can use to assess patient perceptions of prescription drug risk, benefit, and efficacy and to ensure greater future comparability between studies.